Clinical Trial Update: Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial update describing dosing requirements of Astagraf XL in African American kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunosuppression
• Kidney Transplantation

Drugs mentioned

• Astagraf XL (Tacrolimus)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Immunosuppression | Phase 4 | Status: COMPLETED | Results posted: 2019-12-26